Blab Business
Anthropic Unveils Life-Science-Focused AI Model Amid Industry Pushback on Data and Compute Costs
Anthropic announced on Thursday a new large‑language‑model (LLM) designed for the life‑science sector. The company said the model is already in use by major pharmaceutical firms, including Sanofi and Novo Nordisk, and that it will soon begin developing drugs itself. The announcement follows a wave of comments from industry leaders warning that enterprises may be paying for compute twice – once for tokens and again for the data that fuels Anthropic’s models.
Founded in 2021 by former OpenAI employees Daniela and Dario Amodei, Anthropic has positioned itself as a safety‑first AI company. Its flagship Claude series has been adopted by a growing list of enterprise customers, and the firm recently acquired the New York‑based biotech startup Coefficient Bio for roughly $400 million. According to the company, the new model – dubbed Mythos – is tailored for drug discovery, genomics, and other research areas that require high‑precision reasoning.
The model’s early adopters include Sanofi, Novo Nordisk, and AbbVie, all of whom have integrated Anthropic’s LLMs into their research pipelines. Anthropic also said it will soon start using the model to design new molecules, a move that could blur the line between AI service provider and drug developer.
Industry reaction has been swift. On CNBC, Palantir chief executive Alex Karp warned that enterprises should now wonder whether they’re paying for compute twice: once with tokens, and once with all that data that they’ve been feeding into Anthropic’s models. On the All‑In podcast, venture capitalist David Sacks noted that moving from provider to competitor isn’t new for Anthropic, citing the firm’s history of partnering with and then competing against other AI vendors. Investor Chamath Palihapitiya added that “you are letting the fox into the henhouse,” echoing concerns that companies may be exposing sensitive data to a competitor.
Anthropic’s 41 percent share of the enterprise AI market has made it a target for scrutiny. The company’s focus on life sciences has attracted regulatory attention, and the U.S. Department of Defense has recently placed Anthropic on a supply‑chain risk list after the firm refused to remove contractual prohibitions on mass domestic surveillance and autonomous weapons. A federal judge issued a temporary injunction against the designation, but the dispute highlights the broader tension between commercial AI use and national security.
The conversation about data and compute costs echoes an early Facebook exchange in which Mark Zucker reportedly bragged about the amount of data collected from college students. The leaked conversation, dated 2004, illustrates how data collection practices have long been a point of contention in the tech industry.
Open‑source and locally hosted models are gaining traction as an alternative to commercial LLMs. Some analysts say the cost‑double‑pay concern could accelerate the adoption of open‑source solutions that allow companies to keep data in‑house. Anthropic’s move into drug development, however, may reinforce its position as a key partner for pharma, potentially offsetting the appeal of open‑source models in that sector.
At present, Anthropic is preparing for a series of product releases, including the new Mythos model and a suite of tools for life‑science research. The company has not yet disclosed a pricing strategy for the new model, and it remains to be seen how the market will respond to the dual role of AI provider and drug developer. Investors will be watching the company’s next earnings report for clues on revenue growth from the life‑science vertical and any regulatory developments that could impact its operations.
In the coming weeks, Anthropic is expected to provide more details on its drug‑development roadmap and to address questions from regulators about data usage. The company’s next public filing will likely include updates on its enterprise market share and any changes to its pricing model.
Founded in 2021 by former OpenAI employees Daniela and Dario Amodei, Anthropic has positioned itself as a safety‑first AI company. Its flagship Claude series has been adopted by a growing list of enterprise customers, and the firm recently acquired the New York‑based biotech startup Coefficient Bio for roughly $400 million. According to the company, the new model – dubbed Mythos – is tailored for drug discovery, genomics, and other research areas that require high‑precision reasoning.
The model’s early adopters include Sanofi, Novo Nordisk, and AbbVie, all of whom have integrated Anthropic’s LLMs into their research pipelines. Anthropic also said it will soon start using the model to design new molecules, a move that could blur the line between AI service provider and drug developer.
Industry reaction has been swift. On CNBC, Palantir chief executive Alex Karp warned that enterprises should now wonder whether they’re paying for compute twice: once with tokens, and once with all that data that they’ve been feeding into Anthropic’s models. On the All‑In podcast, venture capitalist David Sacks noted that moving from provider to competitor isn’t new for Anthropic, citing the firm’s history of partnering with and then competing against other AI vendors. Investor Chamath Palihapitiya added that “you are letting the fox into the henhouse,” echoing concerns that companies may be exposing sensitive data to a competitor.
Anthropic’s 41 percent share of the enterprise AI market has made it a target for scrutiny. The company’s focus on life sciences has attracted regulatory attention, and the U.S. Department of Defense has recently placed Anthropic on a supply‑chain risk list after the firm refused to remove contractual prohibitions on mass domestic surveillance and autonomous weapons. A federal judge issued a temporary injunction against the designation, but the dispute highlights the broader tension between commercial AI use and national security.
The conversation about data and compute costs echoes an early Facebook exchange in which Mark Zucker reportedly bragged about the amount of data collected from college students. The leaked conversation, dated 2004, illustrates how data collection practices have long been a point of contention in the tech industry.
Open‑source and locally hosted models are gaining traction as an alternative to commercial LLMs. Some analysts say the cost‑double‑pay concern could accelerate the adoption of open‑source solutions that allow companies to keep data in‑house. Anthropic’s move into drug development, however, may reinforce its position as a key partner for pharma, potentially offsetting the appeal of open‑source models in that sector.
At present, Anthropic is preparing for a series of product releases, including the new Mythos model and a suite of tools for life‑science research. The company has not yet disclosed a pricing strategy for the new model, and it remains to be seen how the market will respond to the dual role of AI provider and drug developer. Investors will be watching the company’s next earnings report for clues on revenue growth from the life‑science vertical and any regulatory developments that could impact its operations.
In the coming weeks, Anthropic is expected to provide more details on its drug‑development roadmap and to address questions from regulators about data usage. The company’s next public filing will likely include updates on its enterprise market share and any changes to its pricing model.
